Watts Ryan J.'s Form 4 filing
Denali Therapeutics Inc. (DNLI) · filed Jul 6, 2021
- Accession no.
- 0001209191-21-045422
- Filed
- Jul 6, 2021
- Trade date
- Jul 1, 2021
- Filing delay
- 5 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 3 non-derivative transactions. Open-market sales total $1.42M. It was filed 5 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Watts Ryan J.CIK 0001724310 | Director, Officer (President and CEO) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jul 1, 2021 | Common Stock | SSaleDisposed | −3,030 | $76.38F2 | −$231,431.4 | 2,207,712 | Indirect | |
| Jul 1, 2021 | Common Stock | SSaleDisposed | −12,844 | $77.35F4 | −$993,483.4 | 2,194,868 | Indirect | |
| Jul 1, 2021 | Common Stock | SSaleDisposed | −2,459 | $77.84F5 | −$191,408.56 | 2,192,409 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $75.67 to $76.66 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
Referenced by the price of 1 transaction in Table I.
- F4
The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $76.67 to $77.665 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
Referenced by the price of 1 transaction in Table I.
- F5
The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $77.67 to $78.25 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
Referenced by the price of 1 transaction in Table I.